AstraZeneca reveals designs for new global R&D center and HQ in Cambridge, UK

20 July 2014

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) on Friday revealed designs for its planned network of glass-walled laboratories as part of its new £330million ($564 million) global headquarters at the Cambridge Biomedical Campus (CBC), which is due to be occupied by the end of 2016.

The building, inspired by a traditional Cambridge college, has a grassy quad in the centre and is almost entirely made of glass. Its ground floor level will be open to the public. Herzog & de Meuronare the architects selected to design the new site in Cambridge.

Pascal Soriot, chief executive, unveiled the move to Cambridge after he took the helm two years ago, in an effort to tap into the City’s academic talent and expertise in biomedical science. The plans then formed a key plank in fending off the £69 billion unsolicited takeover approach by the USA’s Pfizer earlier this year. Pfizer had committed to keeping 20% of the combined company’s researchers in the UK, and also continue the headquarters move to Cambridge.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK